secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021113
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen Q4 revenue $75.9M (-14% YoY); FY net loss $102.4M, adj EBITDA -$37.8M
----------------------------------------------------------------------------

- Q4 revenue $75.9M vs $88.1M YoY; full-year revenue $315.7M vs $377.2M in 2022.
- Q4 GAAP net loss $26.6M vs $56.6M loss YoY; adjusted net loss $19.4M vs $13.0M loss.
- Full-year GAAP net loss $102.4M vs $83.8M loss; adjusted EBITDA -$37.8M vs -$13.5M.
- Cash, equivalents and marketable securities $128.5M, no debt; gross margin improved to 37.1% in Q4.
- New CCO Grégoire Ramade and CFO Michael Bourque appointed; focus on Physio-Assist U.S. launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024021113/0000950170-24-021113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024021113/ingn-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer